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Introduction
The ﬁrst administration of a new compound in humans is an
important milestone. A major source of information for the
researcher is the investigator’s brochure (IB). Such a document,
has a size of several hundred pages. The IB should enable in-
vestigators or regulators to independently assess the risk–
beneﬁt of the proposed trial but the size and complexity
makes this difﬁcult. This article offers a practical tool for the
integration and subsequent communication of the complex
information from the IB or other relevant data sources. This
paper is accompanied by an accessible software tool to con-
struct a single page colour coded overview of preclinical and
clinical data.
The tool
In practice, the way in which all the preclinical information
provided in the IB is handled and interpreted is left to profes-
sional discretion of investigators and regulators. This lack of
transparency may have contributed to the oversight in the
trials with TGN1412 and BIAL [1, 2].
The use of preclinical information to design a ﬁrst-in-
human protocol is a complex task, that requires a thorough
understanding of the science and integration of a variety of
data. This integration needs to be critical and goal-directed,
to support the design of a safe and informative study. For a
ﬁrst-in-human study this typically should include the doses
that cover the dose–response curve including the therapeutic
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range, and themeasurements that are predictive of clinical ef-
ﬁcacy and dose-related adverse effects. Although some
knowledge integration systems such as the Napiergram [3]
have been proposed, these have not been widely used and
were not designed to integrate all data in the IB.
The tool essentially consists of a database in which
essential data from all experiments in the IB are entered. This
includes the drug doses, drug concentrations, and pharmaco-
logical, clinical or toxicological effects. This information can
then be sorted on drug concentrations or standardized
human doses, which provides an impression of the dose re-
sponse curves for the desirable and undesirable effects across
the different laboratory animals. Missing information on
drug exposure in some of the experiments can be substituted
from other studies, based on some basic translational and
simple pharmacokinetic assumptions. Such a tool can help
researchers to get a semiquantitative overview of all the pre-
clinical data on which the more complicated assessments
are based. To understand the possibilities and limitations of
the tool, and to avoid misinterpretations, it is important to
start with some of the background of translational drug devel-
opment that underlies the integration of preclinical
experiments.
Translational drug development
Drug development, is an iterative, prototypical process [4]
that typically starts with a series of in silico and in vitro exper-
iments, with the aim of designing a compound with druggable
pharmacochemical and pharmacological properties, which
are considered to be desirable for the new medication. The
different regulatory guidance documents provide an over-
view of the types of preclinical studies that are typically re-
quired for drug development, which are summarized in the
IB [5, 6]. Translational drug development heavily relies on
the assumption that all these results are connected by phar-
macology and pharmacokinetics, in a way that is predictive
of the expected effects in healthy humans and patients. The
consequence of this is that it should be possible to integrate
the data in a more or less quantitative way. However, before
any human predictions are made, it is essential that the
translatability of the drug across species is scrutinized.
Particularly difﬁcult assumptions that should be critically
evaluated [2] are the relevance of animal models for human
disease (to prevent inadequate dose predictions or lack of
efﬁcacy in clinical trials), and the role of the drug’s mode(s)
of action in human physiology (where discordance could
lead to anything from inefﬁcacy to unexpected and
sometimes devastating [7] adverse effects). A critical attitude
is particularly important for first-in-class drugs with a new
mechanism of action.
An important feature of a reliably translatable compound,
is the fact that comparable effects (desired or adverse) in dif-
ferent laboratory animals are found in equivalent ranges of
exposure. Agreement between species improves the predict-
ability for humans [8], but many animal models are restricted
to one species, and have only been validated for a single drug
class. However, if the drug shows signs of therapeutic effects
in one or two animal models at comparable low
concentrations, and undesirable effects at consistently
higher levels in other species, this increases the chance
that the therapeutic window will also be translatable to
humans. Deviations from these predictive characteristics
creates uncertainty about the translatability, particularly
for compounds with a new mode of action. This may have
consequences for the design and execution of studies in
humans.
Predictions of starting dose and
anticipated effective dose
If the drug is expected to be translatable, questions arise
about the predicted dose response relations in humans.
There are different ways to determine the anticipated effective
dose and the starting dose for a ﬁrst-in-human study. The IB
often contains several approximations. This has the advan-
tage that the prediction is more reliable if all approaches
have a similar outcome, and that the use of the most conser-
vative estimate provides an additional safety margin. The
most traditional approach is based on the dose that pro-
duces no adverse effects in the most sensitive species (the
no observable adverse effect level, NOAEL), with an arbitrary
safety factor. This is based on the idea that the predicable
adverse effects are typically caused by the same pharmaco-
logical mechanism. If the NOAEL is not linked to a clear
pharmacological effect, predictions of a safe starting dose
principally rely on the assumption that humans are unlikely
to be more sensitive to the drug than the most sensitive spe-
cies among several investigated laboratory animals (with a
safety factor on top). If the drug is not very toxic, a
NOAEL-based starting dose may already be pharmacologi-
cally active, which can reduce the determined safety margin
of highly selective compounds by overestimating the active
dose [4]. This may also contribute to the sizeable proportion
of modern drugs that require dose reductions after launch
[9]. Since a starting dose that is based on adverse effects
may already be pharmacologically active, a pharmacologically
active dose (PAD) can be determined, which is the lowest
dose that produces a measurable pharmacological effect in
the most sensitive species. A more pharmacologically-based
approach is to estimate the minimum anticipated biological
effect level (MABEL) [10, 11]. This method takes account of
the mechanism of action of the drug, and integrates the
concentrations required to achieve a marginal pharmaco-
logical effect with the expected physiology-based pharma-
cokinetic properties of the drug in humans, including
penetration into the site of action and the level of target
binding and receptor occupancy required for a minimal
pharmacological effect. For this, determining the MABEL
often requires some form of pharmacokinetic (PK)–pharma-
codynamic-type modelling, which makes use of all relevant
preclinical data wherever possible [10]. The interpretation
of NOAEL, PAD and MABEL should be always interpreted
taking into account the relevance of animal models of
safety and efﬁcacy for humans. The NOAEL method tries
to determine the highest safe starting dose, whereas PAD
and MABEL focus on the lowest dose with a biological
effect.
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Translating animal doses into the
human equivalent
All methods that use preclinical data to predict effective con-
centrations or doses in humans, not only rely on the translat-
ability of the drug’s mechanism of action, but also on
pharmacokinetic properties. There are several recommended
ways to estimate the human equivalent dose (HED) for different
animal species and administration modes. The simplest
method consists of dose normalization on an mg kg–1 basis
with a ﬁxed conversion factor for each laboratory species, that
ranges from 0.08 for the mouse to 0.95 for the mini-pig
(Table 1) [12]. It is essential to realize that these allometric
scaling factors can differ considerably, for instance related to
differences in metabolism or kinetic nonlinearity. In these
cases, predictions can be misleading, not only for human
equivalent doses, but also safety factors andNOAELs for the an-
imals that violate the underlying assumptions. PK differences
are more carefully taken into account with aMABEL-approach,
which recommends a more sophisticated physiologically-
based PK (PBPK) or PK/pharmacodynamic analysis [10].
A model-based integration of preclinical data is the best
practice for the determination of the starting dose and the
anticipated effective dose range in humans. However, it is
not always possible to reliably integrate all preclinical
experiments in a model. The guidelines offer the possibility
to disregard data that are difﬁcult to incorporate into the
model. The exclusion of obstinate data may lead to a biased
interpretation. Moreover, such data may be highly relevant
for human dose prediction, because they may reﬂect
problems with safety or with the generalization across species
or experiments.
Dealing with incomplete data in
preclinical experiments
A systematic overview of the studies that are included in the
IB [5, 6], has to deal with the diversity of the preclinical exper-
iments, and the different types of information that they
provide. Ideally, all studies would specify the dose and the
resulting plasma (and tissue) drug concentration proﬁle, in
relation to the pharmacological, clinical or toxicological ef-
fects. Unfortunately, few experiments, if any, provide all this
information. Most studies in the IB are dedicated to one spe-
ciﬁc study result. Consequently, the information that is miss-
ing will have to be constructed from other experiments.
Almost all studies provide the administered dose, but the
problem with sorting on dosage is that dose is not simply
related to concentrations and effects across species. The pre-
dictability can be improved somewhat by normalization of
all experiments to the human equivalent dose, using the
species-speciﬁc conversion factor listed in the guideline [12]
and replicated in Table 1. The limitation of this method is
that the HED conversion factors are based on allometric scal-
ing of body surface area, which is sufﬁciently conservative to
be safe at higher doses, but not accurate enough in a lower
pharmacologically active dose range [13]. The limitation for
Table 1
Conversion factors for human equivalent dose (from [12])
To convert animal dose
in mg kg–1, either:
Reference body
weight (kg)
Working weight
range (kg)
Body surface
area (m2)
To convert dose in mg kg–1
to dose in mg m–2,
multiply by Km
Divide animal
dose by
Multiply animal
dose by
Human 60 - 1.62 37 - -
Child (20 kg) 20 - 0.80 25 - -
Mouse 0.02 0.011–0.34 0.007 3 12.3 0.081
Hamster 0.08 0.047–0.157 0.016 5 7.4 0.135
Rat 0.15 0.08–0.27 0.025 6 6.2 0.162
Ferret 0.30 0.16–0.54 0.043 7 5.3 0.189
Guinea pig 0.40 0.208–0.700 0.05 8 4.6 0.216
Rabbit 1.8 0.90–3.0 0.15 12 3.1 0.324
Dog 10 5.0–17 0.50 20 1.8 0.541
Monkey 3 1.4–4.9 0.25 12 3.1 0.324
Marmoset 3.50 0.14–0.72 0.06 6 6.2 0.162
Squirrel monkey 6.00 0.29–0.97 0.09 7 5.3 0.189
Baboon 12 7.0–23 0.60 20 1.8 0.541
Micro pig 20 10–33 0.74 27 1.4 0.730
Mini pig 40 25–64 1.14 35 1.1 0.946
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a dose-based data arrangement is essentially that this type of
dose-normalization ignores most differences related to ab-
sorption, distribution, metabolism and excretion, which
can vary widely between species and formulations. Although
these factors can be reconciled in a PBPK-analysis, their allo-
metric scaling is complex [13], and the differences between
species preclude a simple dose-based arrangement of preclin-
ical experiments and a straightforward derivation of plasma
concentrations from administered doses. In most cases, how-
ever, predictions of maximum plasma drug concentrations
(Cmax) after administration of a single (weight-corrected, par-
enteral) dose are reasonably accurate across laboratory ani-
mals. This is based on the fact that the apparent volume of
distribution is one of the more reliable allometrically scalable
factors [12, 13]. A graph of the Cmax or the area under the
curve against the HED for different species will readily show
any deviation in a species and will help to give a rough esti-
mate the Cmax in situations where this is not measured.
Drug distribution can be inﬂuenced by species-speciﬁc dif-
ferences in protein binding and transport [14] . These complica-
tions may necessitate PBPK-type analysis at a later stage, but
they can be ignored for the initial simple systematic overview
of preclinical study results that is described here. Absorption
and ﬁrst pass metabolism can also vary widely across species,
but a systematic evaluation of the IB will identify large differ-
ences between oral and parenteral dosing, if the two routes
show different dose–concentration relationships.
Constructing the tool
Information has to be extracted from the Investigational
Medicinal Product Dossier/IB to generate an overview of the
different (pre)clinical experiments. The tool to enter and view
the extracted data can be found at www.ib-derisk.org, and a
tutorial on using the tool is available at https://www.youtube.
com/watch?v=6BJSbpYeKLo&feature=youtu.be. Similar results
can also be ontained by using a simple self-constructed spread-
sheet. The information collected with the tool can be arranged
in different columns of a spreadsheet, which is shown in
Figure 1. Other types of information can be added as separate
columns, for instance, concentrations ofmetabolites, total expo-
sure orhuman equivalent dose. Despite their indicated drawbacks,
HEDs are used inmany IB’s to calculate the recommended starting
dose or the maximum dose from NOAELs (using the species-
speciﬁc allometric values provided in Table 1). Therefore, a
column is added that calculates the HED automatically from
species-speciﬁc scaling factors provided in the guideline. The on-
line tool makes these calculations automatically.
Step 1. Entry of PK experiments
The ﬁrst step in the arrangement of the preclinical experiments
is to select all the single-dose pharmacokinetic studies in the IB,
startingwith a single species (usually rats), and to enter the dose
(inmg kg–1) and themaximum concentration after administra-
tion Cmax (normalized for units for which there are conversion
tools in the program) in the database. If a study involves differ-
ent doses, each dose will be considered a separate experiment.
At this stage, the Cmax-values of the experiments can be sorted
on administration route, whichwill provide a rough impression
of the bioavailability of the compound, for instance by compar-
ing the slopes of the dose-concentrations graphs for the differ-
ent routes. This can be checked against the formal
bioavailabilityvalues,which are often speciﬁed in the IB. Theor-
ganization of the single dose PK data can be done for all the lab-
oratory species where this information is available. Dedicated
PK experiments usually do not involvemeasurements of effects,
but any observations about the condition of the animals are
added to the spreadsheet database, in the clinical effects column.
Step 2. Estimation of missing Cmax
values
The second step requires entry of the non-PK studies that use
a single dose of the compound in the same species for which
separate PK experiments were entered in step 1. The aim of
this is to estimate concentrations at which certain dynamic
Figure 1
Basic structure of the spreadsheet with colour codes. AUC, area under the concentration curve; Cmax, maximum plasma drug concentration; HED,
human equivalent dose
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effects took place. These studies can have different objectives,
such as acute pharmacological effects, tissue penetration, car-
diovascular safety, disease models or toxicology. Studies that
are devoted to drug effects do not usually provide PK values,
so they cannot be sorted directly on Cmax. However, the miss-
ing Cmax values can be reasonably accurately inferred from
the PK-studies in the same species that use the same dose. Af-
ter step two, the database can be sorted on Cmax, which will
be derived from dedicated PK-experiments with measured
Cmax-values, as well as effect studies where these values are
imputed. The amount of inference of the data at this stage is
still limited, and the studies provide fairly homogeneous in-
formation on both the pharmacokinetics and the effects after
acute dosing, in different experiments that usually involve
more than one study per species. For a translatable com-
pound, this integrated information will form a reasonably
solid backbone in the database, which will support the incor-
poration of experiments that lack consistent single dose PK
data. The tool has a facility for the display of graphics to sup-
port this.
Figure 2
Example of a well-behaved translatable compound, sorted on maximum plasma drug concentration (Cmax). Text in the table is omitted for clarity.
Results are randomly mixed across species. For top to bottom, colours gradually change from predominantly blank (no effect) in lowest concen-
tration range through green (pharmacologically or therapeutically desirable) to yellow–orange (increasingly severe reversible adverse effects) and
red (irreversible toxicity and death). The anticipated effective human dose (blue) is in the same region as other green preclinical experiments. An
overview with this colour distribution will provide the investigator with conﬁdence that there are no signiﬁcant differences across species, and that
it is possible to determine a reliable safe starting dose for the ﬁrst study in humans. The reliability is increased by the fact that three species dem-
onstrate the same Cmax vs. human equivalent dose (HED) relationship. (inset) The accuracy of the predictions can be checked during the ﬁrst-in-
human studies, by inserting the actual results. AUC, area under the concentration curve
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Step 3. Estimation of missing Cmax for
other species
The ﬁrst two steps of the entry process include many ex-
periments in the IB, but we are still left with the studies
that do not allow a good estimation of the acute effects
around Cmax. This includes the multiple dose experiments
and some of the acute toxicology studies in another
species, and sometimes models of special interest in a
speciﬁc laboratory animal.
The third step will be to enter the typical information for
these studies (like species, dose, treatment duration and ef-
fects) in the respective ﬁelds of the database. Most of these
studies provide limited PK data at no more than a few time
points after dosing, but not on Cmax. However, since these
studies are really about speciﬁc effects, drug levels that
correspond to these effects are more relevant than accurate
Cmax-values. These levels are often provided for the
experiment, but if not, relevant concentrations can be ap-
proximated with some basic PK assumptions. PK data from a
single dose experiment with the same species may be safely
used to estimate drug levels for a MAD-study, if necessary as-
suming accumulation if the half-life is long. At the very high
end of the dose range (with toxicology studies), an accurate de-
termination of concentrations is less critical for the overview.
Some toxicokinetic data are often provided in the IB, but if
PK data are only available for a lower dose range in the same
species, an alternative option (or a check of the toxicokinetics)
may be to extrapolate concentrations from the higher doses in
the dedicated kinetic studies or from a dose-concentration
graph made in the spreadsheet. This third step will provide a
way to enter all the remaining data without PK information
in the spreadsheet, and to sort all the experiments on their best
estimated concentrations values.
Step 4. Separating the good from the
bad with colour coding
Arranging the information on Cmax (measured, inferred or es-
timated) will give an oversight of the relationships between
Figure 3
Compound without yellow tolerable side effects, signifying a steep concentration-effect relationship with a limited safety margin if dose escalation
is based on symptoms. Text in the table is omitted for clarity. There is a larger safety margin for the anticipated effective dose in humans, which can
potentially be managed by careful rolling assessment of relevant pharmacological activity during ﬁrst-in-man studies. The compound was safely ad-
ministered to humans, based on measures of pharmacological activity and safety that were rapidly analysed and used for dose-escalation decisions. AUC,
area under the concentration curve; Cmax, maximum plasma drug concentration; HED, human equivalent dose
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concentrations and effects across species, but only after closer
examination of the contents of the effects ﬁelds. Some of the
experiments will provide information on more desirable
and others on neutral or more detrimental effects of the
compound, but it may be hard to identify patterns, just on
the descriptions of the effects. To improve the overview, the
fourth step of the process will be to colour code the
experiments, based on the observations in the effects column
using a standardized colour scheme (Figure 1). Sometimes, a
laboratory experiment may report an unexpected death in a
single animal, and there may be doubts about the cause or
the drug relatedness. Even if it seems entirely plausible that
the event is unrelated to the drug, it is generally prudent to
set the colour code to red, because the lack of a relationship
with the drug will usually become clear when all the
experiments are sorted.
Reading the colour codes
After colour coding, the arrangement of the experiments on
Cmax will provide a clear visual impression of the relations be-
tween rising drug concentrations and increasingly intense ef-
fects across species (see Figure 1). The pattern of changes of
the colour provides an impression of the shape of the
concentration–effect curve of the compound. A shallow
curve is suggested by a gradual change when some white
and a fair number of green-coded experiments at lower con-
centrations are followed by a range of acceptable yellow side
effects, before unacceptable orange and red toxicity appears
in the high concentration range (Figure 2). If the green exper-
iments suddenly give way to orange or red studies with very
little yellow in between, it seems that the concentration–
effect curve is steeper. This could also be due to a low number
Figure 4
Discrepancy between animal model (lower blue row) and human predictions (upper blue row); possibly indicative of incorrect prediction by the
model. Text in the table is omitted for clarity. Additionally, the relationship between maximum plasma drug concentration (Cmax) and human
equivalent dose (HED) varies considerably between species, thus inducing further uncertainty about predictions (inset). Product was abandoned.
AUC, area under the concentration curve
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of experiments in the upper safe range, but this will be shown
by a simple check of the concentration range that corre-
sponds to experiments with undesirable but manageable (yel-
low) effects (Figure 3). An apparently sudden occurrence of
toxicity after a limited increase of concentrations is not a very
comfortable situation. Whether this can be acceptable for an
ascending dose study in humans, depends on the expected
safety window. If many green experiments are available
across a wide range of doses and concentrations, it may still
be possible to determine a maximal dose that remains com-
fortable below the orange/red zone, by careful measurement
of the pharmacological activity of the drug. At any rate, an
apparently steep concentration–effect curve with sudden oc-
currence of severe adverse effects should lead to discussions
between the investigator team and the sponsor about adapta-
tion of the design of the human studies.
The homogeneous colour-coded patterns after arrangement
onCmax that have been described so far, offer a relatively straight-
forward interpretation. These patterns also suggest that the drug
behaves relatively similarly between different strains and species
(as far as these have been examined). The pattern may also be
more irregular and show, for instance, an experiment with a
severe adverse effect (orange- or red-coded), which seems to dis-
rupt a range of concentrations that otherwise provide only neu-
tral or desirable effects (blank or green). Such irregularities
obviously require a search for the cause, whichmay include inap-
plicability of animalmodels (Figure 4) or unexpected toxicity that
may be species speciﬁc (Figure 5). If a certain type of drug toxicity
only develops after chronic dosing (as indicated in the duration
ﬁeld of the database), these experiments will also disrupt the pat-
tern if the spreadsheet is sorted on acute (inferred) Cmax values.
In these cases, the single dose experiments with the same dosages
will show fewer adverse effects than the multiple dose studies.
There are also cases where the irregularities in the pattern
reﬂect problems with the translatability of the compound. A
single species or strain may more sensitive to the drug than
others, and my show toxicity in a green range that corresponds
with desirable effects in other animals. If no clear reason can be
identiﬁed why one species responds differently from the rest,
this adds to the uncertainty about the predictability for
humans. In general, conﬁdence in the predictability of the
overview, not only depends on the concentration-effect pat-
tern in the spreadsheet, but also on the number of experiments
within each colour-coded category.
Figure 5
Reduction of safety margin caused by unexpected toxicity ﬁndings at drug concentrations slightly above therapeutic levels (red rows). Text in the
table is omitted for clarity. This indicated possible species-speciﬁc toxicity, which might have been derisked by elucidation of mechanism of action. In-
stead, it was decided to stop further development. The compound was not administered to humans. AUC, area under the concentration curve; Cmax,
maximum plasma drug concentration; HED, human equivalent dose
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Spreadsheet-based IB overviews
Over the course of the years, the spreadsheet procedure de-
scribed in this article has become a standard way in our insti-
tution of evaluating the IB for novel compounds, and there is
now experience with several dozens of compounds. The
spreadsheets almost invariably improved the communica-
tion among the teams of investigators and sponsors regarding
an otherwise potentially complete but very large amount of
unrelated data. During the ﬁrst-in-human studies, the data-
base is updated with emerging data from consecutive doses.
Often, these data are in line with expectations, but some-
times predictions and dose ranges need to be adapted
(Figure 6). The incorporation of actual human data into the
overview of nonclinical experiments is useful for discussions
about maximum dosages or dose escalation steps, and pro-
vides constant feedback on the translatability of the com-
pound and the reliability of underlying assumptions.
The total set of preclinical data preceding a ﬁrst-in human
experiment is very large, often encompassing several hundred
pages, and needs to be assessed by the company, the investigator
and regulatory agencies. They will all be assisted by a
standardized tool that allows the evaluation of all the data in
relation to each other. The software tool is freely available at
www.ib-derisk.org together with an instruction video. Clearly,
the current tool is a simplemethod to create order in a relatively
unconnected set of data. There is no computer tool that can re-
place experience or sound clinical judgement required to take
the complex decisions required during early drug development.
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